Approval · Notice of Compliance 24334 · 2020
ACT DAPTOMYCIN: Notice of Compliance 24334
Issued October 1, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24334
- Date
- October 1, 2020
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- CUBICIN (Cubist Pharmaceuticals Llc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT DAPTOMYCIN | 02462117 | Cancelled Pre Market |
Medicinal ingredients
- DAPTOMYCIN 500 MG per VIAL